插图描绘冠状动脉的动脉粥样硬化。
冠状动脉疾病（CAD），也称为缺血性心脏病（IHD），[13]是最常见的心血管疾病。[14]类型包括稳定型心绞痛，不稳定型心绞痛，心肌梗死和心源性猝死[15]。常见的症状是胸痛或不适，可能会进入肩部，手臂，背部，颈部或下颌。[4]偶尔它可能会像胃灼热一样。通常症状出现在运动或情绪压力下，持续时间不到几分钟，并随着休息而改善。[4]也可能出现呼吸短促，有时无症状。[4]在许多情况下，第一个迹象是心脏病发作。[5]其他并发症包括心力衰竭或心跳异常。[5]
风险因素包括高血压，吸烟，糖尿病，缺乏运动，肥胖，高血脂，饮食不良，抑郁和过量饮酒。[6] [7] [16]潜在的机制包括由于心脏动脉的动脉粥样硬化而减少血流和氧气到心肌。[6]许多测试可能有助于诊断，包括：心电图，心脏压力测试，冠状动脉计算机断层扫描血管造影和冠状动脉造影等。[8]
降低CAD风险的方法包括健康饮食，定期锻炼，保持健康体重，不吸烟。[9]有时使用糖尿病，高胆固醇或高血压的药物。[9]筛查风险低且没有症状的人的证据有限。[17]治疗涉及与预防相同的措施。[10] [18]可能会推荐其他药物，如抗血小板药（包括阿司匹林），β受体阻滞剂或硝酸甘油。[10]经皮冠状动脉介入治疗（PCI）或冠状动脉搭桥手术（CABG）等手术可用于严重疾病[10] [19]。在那些CAD稳定的患者中，除了其他治疗方法外，PCI或CABG是否可以改善预期寿命或降低心脏病发作风险尚不清楚。[20]
2015年，加元影响了1.1亿人，导致890万人死亡。[11] [12]它占所有死亡人数的15.6％，使其成为全球死亡的最常见原因。[12] 1980年至2010年期间，特定年龄的CAD死亡风险下降，特别是在发达国家。[21] 1990年至2010年期间，特定年龄的CAD病例数也有所减少。[22]在2010年的美国，65岁以上人群中约有20％患有冠心病，而45岁至64岁患者中有7％患有冠心病，而18至45岁患者则为1.3％; [23]男性患者的发病率高于女性特定年龄。[23]
视频：↓ 冠心病，动脉阻塞和动脉粥样硬化
https://cache.tv.qq.com/qqplayerout.swf?vid=m0816royhhj
目录
1 症状和体征
2 风险因素
2.1 血脂
2.2 遗传学
2.3 其他
3 病理生理学
4 诊断
4.1 稳定型心绞痛
4.2 急性冠脉综合征
4.3 风险评估
5 预防
5.1 饮食
5.2 二级预防
6 治疗
6.1 药物治疗
6.2 手术
7 流行病学
8 社会与文化
8.1 命名
8.2 支持小组
8.3 行业对研究的影响
9 研究
10 参考
体征和症状
经常活动，进食后或在其他可预测的时间发生的胸痛被称为稳定性心绞痛并且与心脏动脉狭窄有关。
强度，性格或频率变化的心绞痛被称为不稳定。不稳定型心绞痛可能发生在心肌梗死之前。对于因疼痛原因不明确而去急诊室的成年人，约有30％的人因冠状动脉疾病而感到疼痛。[24]
风险因素
冠状动脉疾病有许多明确的危险因素。这些包括高血压，吸烟，糖尿病，缺乏运动，肥胖，高血脂，饮食不良，抑郁，家族史和过量饮酒。[6] [7] [16]大约一半的病例与遗传有关。[25]吸烟和肥胖分别与约36％和20％的病例有关。[26]每天只吸一支烟，大约会增加CAD的风险。[27]缺乏锻炼与7-12％的病例有关。[26] [28]接触除草剂橙剂可能会增加风险。[29]类风湿性关节炎，系统性红斑狼疮，牛皮癣和银屑病关节炎等风湿性疾病也是独立的危险因素。[30] [31] [32] [33]
工作压力似乎起了次要作用，约占案件的3％。[26]在一项研究中，没有工作压力的女性血管直径增加，导致动脉粥样硬化进展减少。[34]相比之下，工作压力较高的女性血管直径减小，疾病进展明显增加。[34]具有A型行为模式，一组人格特征，包括时间紧迫性，竞争力，敌意和不耐烦，[35]与冠心病风险增加有关。[36]
血脂
高血胆固醇（特别是血清LDL浓度）。 HDL（高密度脂蛋白）对冠状动脉疾病的发展具有保护作用。[37]
高血甘油三酯可能起作用。[38]
高水平的脂蛋白（a），[39] [40] [41]当LDL胆固醇与称为载脂蛋白（a）的蛋白质结合时形成的化合物。
膳食胆固醇似乎对血液胆固醇没有显着影响，因此可能不需要有关其消费的建议。[42]饱和脂肪仍是一个问题。[42]
遗传学
据估计，冠状动脉疾病的遗传率在40％至60％之间。[43] 全基因组关联研究已经确定了大约60个冠状动脉疾病的遗传易感位点。[44]
其他
40岁以下妇女的子宫内膜异位症。[45]
抑郁和敌意似乎是风险。[46]
儿童不良经历（心理，身体或性虐待;对母亲的暴力行为;或与滥用药物，精神病，自杀或被监禁的家庭成员一起生活）的类别数量与成人疾病的存在呈现分级相关性，包括 冠状动脉（缺血性心脏病）。[47]
止血因子：高水平的纤维蛋白原和凝血因子VII与CAD风险增加有关[48]。
低血红蛋白。[49]
在亚洲人群中，b纤维蛋白原基因G-455A多态性与CAD的风险相关[50]。
病理生理学
冠状动脉的显微照片，最常见的冠状动脉疾病（动脉粥样硬化）和明显的管腔狭窄。 Masson's三色。
插图描绘冠状动脉疾病
对心脏的血流量的限制导致心脏肌细胞的缺血（继发于缺氧的细胞饥饿）。心脏的肌肉细胞可能因缺氧而死亡，这被称为心肌梗塞（通常称为心脏病发作）。它会导致心肌的损伤，死亡和最终疤痕，而不会使心肌细胞再生。慢性高级别的冠状动脉狭窄可以诱发短暂性缺血，导致室性心律失常的诱发，这可能终止于称为心室颤动的危险心律，这常常导致死亡。[51]
通常，当冠状动脉内的光滑弹性衬里（向心肌供血的动脉）的一部分发生动脉粥样硬化时，就会发生冠状动脉疾病。随着动脉粥样硬化，动脉的内层变硬，变硬，并积聚钙，脂肪脂和异常炎症细胞的沉积物 - 形成斑块。血管肌层中的磷酸钙（羟基磷灰石）沉积物似乎在加强动脉和诱导冠状动脉硬化的早期阶段中起重要作用。这可以在所谓的慢性肾病和血液透析中发生的所谓的钙化转移机制中看出（Rainer Liedtke 2008）。虽然这些人患有肾功能不全，但近50％的人因冠状动脉疾病而死亡。斑块可以被认为是突出到动脉通道中的大“丘疹”，导致部分阻塞血流。患有冠状动脉疾病的人可能只有一到两个斑块，或者可能在整个冠状动脉中分布有数十个斑块。当冠状动脉完全阻塞超过3个月时，更严重的形式是慢性完全闭塞（CTO）。[52]
心脏综合征X是在进行血管造影（冠状动脉造影）时心脏较大的冠状动脉没有出现阻塞迹象的人的胸痛（心绞痛）和胸部不适。[53]心脏综合征X的确切原因尚不清楚。解释包括微血管功能障碍或心外膜动脉粥样硬化。[54] [55]由于理解不充分的原因，女性比男性更有可能拥有它;然而，女性独有的激素和其他风险因素可能起作用。[56]
诊断
一名男子的冠状动脉造影
一名妇女的冠状动脉造影
对于有症状的人，应力超声心动图可用于诊断阻塞性冠状动脉疾病。[57]对于没有出现症状且发生冠心病的风险较低的个体，不推荐使用超声心动图，应力心脏成像和/或高级非侵入性成像。[57] [58]
“心脏综合症X”的诊断 - 如上所述，在女性中更常见的罕见冠状动脉疾病是诊断排除。因此，通常使用与怀疑患有冠状动脉疾病的任何人相同的测试：
基线心电图（ECG）
运动心电图 - 压力测试
运动放射性同位素试验（核应激试验，心肌闪烁扫描）
超声心动图（包括压力超声心动图）
冠状动脉造影
血管内超声
磁共振成像（MRI）
特定症状的冠状动脉疾病的诊断在很大程度上取决于症状的性质。第一项调查是心电图（ECG / EKG），用于“稳定”心绞痛和急性冠状动脉综合征。可以进行胸部X光检查和血液检查。
稳定的心绞痛
主要文章：心绞痛
在“稳定”心绞痛，胸痛伴有可预测的运动水平的典型特征，各种形式的心脏压力测试可用于诱导两种症状并通过心电图（使用ECG）检测变化，超声心动图（使用超声心动图）心脏）或闪烁扫描（使用心肌摄取放射性核素）。如果部分心脏似乎血液供应不足，冠状动脉造影可用于识别冠状动脉狭窄和血管成形术或旁路手术的适用性。[59]
稳定型冠状动脉疾病（SCAD）通常也称为稳定性缺血性心脏病（SIHD）。[60] 2015年专着解释说“无论命名如何，稳定性心绞痛是SIHD或SCAD的主要表现。”[60] SIHD / SCAD有美国和欧洲的临床实践指南。[61] [62]
急性冠状动脉综合征
主要文章：急性冠脉综合征
急性冠状动脉综合征的诊断通常在急诊室进行，其中可以顺序执行ECG以识别“进化的变化”（指示对心肌的持续损伤）。如果ECG显示“ST段”的升高，则诊断是明确的，在严重的典型胸痛的情况下，ST段显示急性心肌梗塞（MI）;这被称为STEMI（ST段抬高心肌梗死），无论是哪种可用，都可以通过紧急冠状动脉造影和经皮冠状动脉介入治疗（有或没有支架置入的血管成形术）或溶栓（“血栓破坏”药物治疗）作为紧急治疗。在没有ST段抬高的情况下，通过心脏标记物检测心脏损伤（识别心肌损伤的血液测试）。如果有损伤（梗塞）的证据，则胸痛归因于“非ST段抬高MI”（NSTEMI）。如果没有损伤迹象，则使用术语“不稳定型心绞痛”。这个过程通常需要住院和密切观察冠心病监护室是否存在可能的并发症（如心律失常 - 心率不规律）。根据风险评估，压力测试或血管造影可用于识别和治疗患有NSTEMI或不稳定型心绞痛的患者的冠状动脉疾病。
风险评估
有各种风险评估系统可用于确定冠状动脉疾病的风险，并强调上述不同的变量。一个值得注意的例子是弗雷明汉心脏研究中使用的Framingham Score。它主要基于年龄，性别，糖尿病，总胆固醇，高密度脂蛋白胆固醇，吸烟和收缩压。
预防
如果避免确定的风险因素，高达90％的心血管疾病可以预防。[63] [64]预防包括适当的体育锻炼，减少肥胖，治疗高血压，饮食健康，降低胆固醇水平和戒烟。药物和运动大致同样有效。[65]高水平的身体活动可使冠状动脉疾病的风险降低约25％。[66]
大多数指南建议结合这些预防策略。 2015年Cochrane评价发现一些证据表明这种方法可能有助于血压，体重指数和腰围。然而，没有足够的证据表明对死亡率或实际心血管事件有影响。[67]
在糖尿病中，几乎没有证据表明非常严格的血糖控制可以改善心脏病风险，尽管改善糖控制似乎可以减少其他问题，如肾衰竭和失明。世界卫生组织（WHO）建议“低至中度饮酒”以降低冠状动脉疾病的风险，而高摄入会增加风险。[68]
饮食
主要文章：饮食和心脏病
高水果和蔬菜的饮食可以降低患心血管疾病和死亡的风险。[69]素食者患心脏病的风险较低，[70] [71]可能是因为他们更多地食用水果和蔬菜。[72]证据还表明，地中海饮食[73]和高纤维饮食降低了风险。[74]
消耗反式脂肪（通常存在于人造黄油等氢化产品中）已被证明是导致动脉粥样硬化的前兆[75]并增加冠状动脉疾病的风险。[76]
证据不支持omega-3脂肪酸补充剂在预防心血管疾病（包括心肌梗塞和心源性猝死）方面的有益作用。[77] [78]有初步证据表明，摄入甲基萘醌（维生素K2）而不是叶绿醌（维生素K1）可以降低死亡率的风险。[79]
二级预防
二级预防可以防止已经确定的疾病的进一步后遗症。已被证明对此目标有效的生活方式变化包括：
控制体重
戒烟
避免反式脂肪的消耗（部分氢化油）
减少心理社会压力[80]
行使;有氧运动，如散步，慢跑或游泳，可以降低冠状动脉疾病死亡的风险。[81]有氧运动可以帮助降低血压和血液胆固醇（LDL）的数量。它还会增加HDL胆固醇，这被认为是“好胆固醇”。[82] [83]分开运动的好处问题;目前尚不清楚医生是否应该花时间辅导患者进行锻炼。美国预防服务工作组发现“证据不足”，建议医生为患者提供运动建议，但“它没有检查体力活动有效性的证据，以减少慢性疾病，发病率和死亡率”，它只检查了有效性。辅导。[84]美国心脏协会基于非系统评价，建议医生为患者提供运动建议。[85]
治疗
冠状动脉疾病有多种治疗选择：[86]
改变生活方式
药物治疗 - 药物（如降胆固醇药物，β-受体阻滞剂，硝酸甘油，钙通道阻滞剂等）;
作为血管成形术和冠状动脉支架的冠状动脉介入治疗;
冠状动脉旁路移植术（CABG）
药物
他汀类药物可降低胆固醇，降低患冠心病的风险[87]
硝酸甘油[88]
钙通道阻滞剂和/或β受体阻滞剂[89]
抗血小板药物如阿司匹林[89] [90]
建议血压通常降至140/90 mmHg以下。[91]然而，舒张压不应低于60 mmHg。[含糊]β受体阻滞剂是推荐用于此用途的第一线。[91]
阿司匹林
在没有心脏病史的患者中，阿司匹林可降低心肌梗死的风险，但不会改变总体死亡风险。[92]因此，仅建议患有冠心病风险增加的成年人[93]将风险增加定义为“年龄大于90岁的男性，绝经后妇女和患有冠状动脉疾病危险因素的年轻人（例如，高血压，糖尿病或吸烟）患心脏病的风险增加，并且可能希望考虑“阿司匹林治疗”。更具体地说，高危人群是“5年风险≥3％的人”。
抗血小板治疗
在STEMI患者中，氯吡格雷加阿司匹林（双重抗血小板治疗）比单用阿司匹林更能减少心血管事件。在其他风险较高但没有发生急性事件的情况下，证据不足。[94]具体而言，它的使用不会改变这一群体的死亡风险。[95]在那些支架超过12个月的氯吡格雷加阿司匹林的患者中，不会影响死亡风险。[96]
手术
急性冠状动脉综合征的血运重建具有死亡率的益处。[97]对于稳定的缺血性心脏病，经皮血运重建似乎没有单独使用药物治疗的益处。[98]对于患有多种动脉疾病的患者，冠状动脉旁路移植术似乎优于经皮冠状动脉介入治疗。[99] [100]较新的“主动脉”或非接触式非体外循环冠状动脉血运重建技术显示，与经皮冠状动脉介入治疗相比，术后卒中发生率降低[101]。混合冠状动脉血运重建术也被证明是一种安全可行的方法，虽然费用较高，但可提供优于传统CABG的一些优势。[102]
流行病学
2012年每百万人因缺血性心脏病死亡
2004年每10万居民缺血性心脏病的残疾调整生命年。[103]
截至2010年，CAD是全球死亡的主要原因，导致700多万人死亡。[104]这一数字从1990年全世界的CAD死亡人数增加到520万。[104]它可能影响任何年龄的个体，但在年龄逐渐变大的情况下变得更加普遍，每生命十年大约增加三倍。[105]男性比女性更容易受到影响。[105]
据估计，世界上60％的心血管疾病负担将发生在南亚次大陆，尽管仅占世界人口的20％。这可能是遗传易感性和环境因素相结合的次要因素。印度心脏协会等组织正在与世界心脏联合会合作，以提高对这一问题的认识。[106]
冠状动脉疾病是男性和女性死亡的主要原因，并且每年在美国造成约600,000人死亡。[107]根据美国目前的趋势，一半健康的40岁男性将来会发展为CAD，三分之一的健康40岁女性将会发展。[108]这是美国20岁以上男性和女性死亡的最常见原因。[109]
社会与文化
名称
有时用于这种情况的其他术语是“动脉硬化”和“动脉狭窄”。[110]在拉丁语中，它被称为morbus ischaemicus cordis（MIC）。
支持小组
Infarct Combat Project（ICP）是一家成立于1998年的国际非营利组织，致力于通过教育和研究来减少缺血性心脏病。[111] [112]
行业对研究的影响
在2016年对[未引用的]档案的研究，糖业协会，美国制糖业的行业协会，赞助了1965年在新英格兰医学杂志上发表的一篇有影响力的文献综述，该评论淡化了早期的研究结果。饮食中重糖的作用在CAD的发展中强调脂肪的作用;该评论影响了数十年的研究经费和健康饮食指导。[113] [114] [115] [116] [117]
研究
进一步的信息：动脉粥样硬化和动脉粥样硬化
研究工作集中在新的血管生成治疗方式和各种（成人）干细胞疗法。 17号染色​​体上的一个区域仅限于多发心肌梗死病例的家庭。[118]其他全基因组研究已经在9号染色体上发现了一个确定的风险变异（9p21.3）。[119]然而，这些和其他基因座存在于基因间片段中，需要进一步研究以了解表型如何受到影响。[120]
一个更有争议的联系是肺炎衣原体感染和动脉粥样硬化之间的关系。[121]虽然这种细胞内生物体已在动脉粥样硬化斑块中得到证实，但关于它是否可被视为致病因素的证据尚无定论。[122]在已证实的动脉粥样硬化患者中使用抗生素治疗并未证明心脏病发作或其他冠状动脉血管疾病的风险降低。[123]
自20世纪90年代以来，寻找冠状动脉疾病患者的新治疗方案，特别是对于所谓的“无选择”冠状动脉患者，主要关注血管生成[124]和（成人）干细胞疗法的使用。 进行了许多临床试验，要么应用蛋白质（血管生成生长因子）治疗，如FGF-1或VEGF，要么使用不同种类的成体干细胞群进行细胞治疗。 研究仍在继续 - 特别是对于FGF-1 [125] [126]和内皮祖细胞的利用的第一个有希望的结果。
髓过氧化物酶已被提议作为生物标志物。[127]
饮食改变可以减少冠状动脉疾病。 例如，数据支持从基于植物的饮食和积极的降脂改善心脏病中获益。[128]
参考：
"Coronary heart disease – causes, symptoms, prevention". Southern Cross Healthcare Group. Archived from the original on 3 March 2014. Retrieved 15 September 2013.
Faxon, D. P. (1 June 2004). "Atherosclerotic Vascular Disease Conference: Executive Summary: Atherosclerotic Vascular Disease Conference Proceeding for Healthcare Professionals From a Special Writing Group of the American Heart Association". Circulation. 109 (21): 2595–2604. doi:10.1161/01.CIR.0000128517.52533.DB. PMID 15173041.
"Coronary heart disease". NIH. Archived from the original on 12 September 2013. Retrieved 15 September 2013.
"What Are the Signs and Symptoms of Coronary Heart Disease?". 29 September 2014. Archived from the original on 24 February 2015. Retrieved 23 February 2015.
"Coronary Artery Disease (CAD)". 12 March 2013. Archived from the original on 2 March 2015. Retrieved 23 February 2015.
Mendis, Shanthi; Puska, Pekka; Norrving, Bo (2011). Global atlas on cardiovascular disease prevention and control (PDF) (1st ed.). Geneva: World Health Organization in collaboration with the World Heart Federation and the World Stroke Organization. pp. 3–18. ISBN 9789241564373. Archived (PDF) from the original on 17 August 2014.
Mehta, PK; Wei, J; Wenger, NK (16 October 2014). "Ischemic heart disease in women: A focus on risk factors". Trends in Cardiovascular Medicine. 25 (2): 140–151. doi:10.1016/j.tcm.2014.10.005. PMC 4336825. PMID 25453985.
"How Is Coronary Heart Disease Diagnosed?". 29 September 2014. Archived from the original on 24 February 2015. Retrieved 25 February 2015.
"How Can Coronary Heart Disease Be Prevented or Delayed?". Archived from the original on 24 February 2015. Retrieved 25 February 2015.
"How Is Coronary Heart Disease Treated?". 29 September 2014. Archived from the original on 24 February 2015. Retrieved 25 February 2015.
GBD 2015 Disease and Injury Incidence and Prevalence, Collaborators. (8 October 2016). "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1545–1602. doi:10.1016/S0140-6736(16)31678-6. PMC 5055577. PMID 27733282.
GBD 2015 Mortality and Causes of Death, Collaborators. (8 October 2016). "Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1459–1544. doi:10.1016/S0140-6736(16)31012-1. PMC 5388903. PMID 27733281.
Bhatia, Sujata K. (2010). Biomaterials for clinical applications (Online-Ausg. ed.). New York: Springer. p. 23. ISBN 9781441969200. Archived from the original on 10 January 2017.
GBD 2013 Mortality and Causes of Death, Collaborators (17 December 2014). "Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013". Lancet. 385 (9963): 117–171. doi:10.1016/S0140-6736(14)61682-2. PMC 4340604. PMID 25530442.
Wong, ND (May 2014). "Epidemiological studies of CHD and the evolution of preventive cardiology". Nature Reviews. Cardiology. 11 (5): 276–89. doi:10.1038/nrcardio.2014.26. PMID 24663092.
Charlson, FJ; Moran, AE; Freedman, G; Norman, RE; Stapelberg, NJ; Baxter, AJ; Vos, T; Whiteford, HA (26 November 2013). "The contribution of major depression to the global burden of ischemic heart disease: a comparative risk assessment". BMC Medicine. 11: 250. doi:10.1186/1741-7015-11-250. PMC 4222499. PMID 24274053.
Desai, CS; Blumenthal, RS; Greenland, P (April 2014). "Screening low-risk individuals for coronary artery disease". Current Atherosclerosis Reports. 16 (4): 402. doi:10.1007/s11883-014-0402-8. PMID 24522859.
Boden, WE; Franklin, B; Berra, K; Haskell, WL; Calfas, KJ; Zimmerman, FH; Wenger, NK (October 2014). "Exercise as a therapeutic intervention in patients with stable ischemic heart disease: an underfilled prescription". The American Journal of Medicine. 127 (10): 905–11. doi:10.1016/j.amjmed.2014.05.007. PMID 24844736.
Deb, S; Wijeysundera, HC; Ko, DT; Tsubota, H; Hill, S; Fremes, SE (20 November 2013). "Coronary artery bypass graft surgery vs percutaneous interventions in coronary revascularization: a systematic review". JAMA. 310 (19): 2086–95. doi:10.1001/jama.2013.281718. PMID 24240936.
Rezende, PC; Scudeler, TL; da Costa, LM; Hueb, W (16 February 2015). "Conservative strategy for treatment of stable coronary artery disease". World Journal of Clinical Cases. 3 (2): 163–70. doi:10.12998/wjcc.v3.i2.163. PMC 4317610. PMID 25685763.
Moran, AE; Forouzanfar, MH; Roth, GA; Mensah, GA; Ezzati, M; Murray, CJ; Naghavi, M (8 April 2014). "Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to 2010: the Global Burden of Disease 2010 study". Circulation. 129 (14): 1483–92. doi:10.1161/circulationaha.113.004042. PMC 4181359. PMID 24573352.
Moran, AE; Forouzanfar, MH; Roth, GA; Mensah, GA; Ezzati, M; Flaxman, A; Murray, CJ; Naghavi, M (8 April 2014). "The global burden of ischemic heart disease in 1990 and 2010: the Global Burden of Disease 2010 study". Circulation. 129 (14): 1493–501. doi:10.1161/circulationaha.113.004046. PMC 4181601. PMID 24573351.
Centers for Disease Control and Prevention, (CDC) (14 October 2011). "Prevalence of coronary heart disease—United States, 2006–2010". MMWR. Morbidity and Mortality Weekly Report. 60 (40): 1377–81. PMID 21993341.
Kontos, MC; Diercks, DB; Kirk, JD (Mar 2010). "Emergency department and office-based evaluation of patients with chest pain". Mayo Clinic Proceedings. 85 (3): 284–99. doi:10.4065/mcp.2009.0560. PMC 2843115. PMID 20194155.
Dai, Xuming; et al. (2016). "Genetics of coronary artery disease and myocardial infarction". World Journal of Cardiology. 8 (1): 1–23. doi:10.4330/wjc.v8.i1.1. PMC 4728103. PMID 26839654.
Kivimäki M, Nyberg ST, Batty GD, Fransson EI, Heikkilä K, Alfredsson L, Bjorner JB, Borritz M, Burr H, Casini A, Clays E, De Bacquer D, Dragano N, Ferrie JE, Geuskens GA, Goldberg M, Hamer M, Hooftman WE, Houtman IL, Joensuu M, Jokela M, Kittel F, Knutsson A, Koskenvuo M, Koskinen A, Kouvonen A, Kumari M, Madsen IE, Marmot MG, Nielsen ML, Nordin M, Oksanen T, Pentti J, Rugulies R, Salo P, Siegrist J, Singh-Manoux A, Suominen SB, Väänänen A, Vahtera J, Virtanen M, Westerholm PJ, Westerlund H, Zins M, Steptoe A, Theorell T (October 2012). "Job strain as a risk factor for coronary heart disease: a collaborative meta-analysis of individual participant data". Lancet. 380 (9852): 1491–97. doi:10.1016/S0140-6736(12)60994-5. PMC 3486012. PMID 22981903.
Hackshaw, Allan; Morris, Joan K; Boniface, Sadie; Tang, Jin-Ling; Milenković, Dušan (24 January 2018). "Low cigarette consumption and risk of coronary heart disease and stroke: meta-analysis of 141 cohort studies in 55 study reports". BMJ. 360: j5855. doi:10.1136/bmj.j5855. PMC 5781309. PMID 29367388.
Lee IM, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT (July 2012). "Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy". Lancet. 380 (9838): 219–29. doi:10.1016/S0140-6736(12)61031-9. PMC 3645500. PMID 22818936.
"Agent Orange: Diseases Associated with Agent Orange Exposure". Department of Veterans Affairs Office of Public Health and Environmental Hazards. 25 March 2010. Archived from the original on 9 May 2010. Retrieved 4 May 2010.
Esdaile, JM; Abrahamowicz, M; Grodzicky, T; Li, Y; Panaritis, C; du Berger, R; Côte, R; Grover, SA; Fortin, PR; Clarke, AE; Senécal, JL (October 2001). "Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus". Arthritis and Rheumatism. 44 (10): 2331–7. doi:10.1002/1529-0131(200110)44:10<2331::aid-art395>3.0.co;2-i. PMID 11665973.
Kerola, AM; Kauppi, MJ; Kerola, T; Nieminen, TV (October 2012). "How early in the course of rheumatoid arthritis does the excess cardiovascular risk appear?". Annals of the Rheumatic Diseases. 71 (10): 1606–15. doi:10.1136/annrheumdis-2012-201334. PMID 22736093.
Roubille, C; Richer, V; Starnino, T; McCourt, C; McFarlane, A; Fleming, P; Siu, S; Kraft, J; Lynde, C; Pope, J; Gulliver, W; Keeling, S; Dutz, J; Bessette, L; Bissonnette, R; Haraoui, B (March 2015). "The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis". Annals of the Rheumatic Diseases (Systematic Review & Meta-Analysis). 74 (3): 480–9. doi:10.1136/annrheumdis-2014-206624. PMC 4345910. PMID 25561362.
Garshick, M; Underberg, JA (October 2017). "The Use of Primary Prevention Statin Therapy in Those Predisposed to Atherosclerosis". Current Atherosclerosis Reports (Review). 19 (12): 48. doi:10.1007/s11883-017-0685-7. PMID 29038899.
Wang HX, Leineweber C, Kirkeeide R, Svane B, Schenck-Gustafsson K, Theorell T, Orth-Gomér K (March 2007). "Psychosocial stress and atherosclerosis: family and work stress accelerate progression of coronary disease in women. The Stockholm Female Coronary Angiography Study". J. Intern. Med. 261 (3): 245–54. doi:10.1111/j.1365-2796.2006.01759.x. PMID 17305647.
Andreassi, John L. (2000). Psychophysiology: human behavior and physiological response. Mahwah, NJ: L. Erlbaum. p. 287.
McCann S.J.H. (November 2001). "The precocity-longevity hypothesis: earlier peaks in career achievement predict shorter lives". Pers Soc Psychol Bull. 27 (11): 1429–39. doi:10.1177/01461672012711004. Archived from the original on 3 September 2015.
Rhodewalt; Smith (1991). "Current issues in Type A behaviour, coronary proneness, and coronary heart disease". In Snyder, C.R.; Forsyth, D.R. Handbook of social and clinical psychology: the health perspective. New York: Pergamon. pp. 197–220. ISBN 978-0080361284.
Underwood and Cross, James (2009). General and Systematic Pathology. London, UK: Churchhill livingstone. p. 279.
Kannel, WB; Vasan, RS (Jul 2009). "Triglycerides as vascular risk factors: new epidemiologic insights". Current Opinion in Cardiology. 24 (4): 345–50. doi:10.1097/HCO.0b013e32832c1284. PMC 3012388. PMID 19424059.
Danesh J, Collins R, Peto R (2000). "Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies". Circulation. 102 (10): 1082–85. doi:10.1161/01.CIR.102.10.1082. PMID 10973834. Archived from the original on 5 July 2011.
Smolders B, Lemmens R, Thijs V (2007). "Lipoprotein (a) and stroke: a meta-analysis of observational studies". Stroke. 38 (6): 1959–66. doi:10.1161/STROKEAHA.106.480657. PMID 17478739.
Schreiner PJ, Morrisett JD, Sharrett AR, Patsch W, Tyroler HA, Wu K, Heiss G (1993). "Lipoprotein(a) as a risk factor for preclinical atherosclerosis" (PDF). Arterioscler. Thromb. 13 (6): 826–33. doi:10.1161/01.ATV.13.6.826. PMID 8499402. Archived (PDF) from the original on 17 May 2011.
"Scientific Report of the 2015 Dietary Guidelines Advisory COmmittee" (PDF). health.gov. Feb 2015. p. Part D, Chapter 1, Page 17 (642). Archived (PDF) from the original on 3 May 2016.
McPherson, R; Tybjaerg-Hansen, A (19 February 2016). "Genetics of Coronary Artery Disease". Circulation Research. 118 (4): 564–78. doi:10.1161/circresaha.115.306566. PMID 26892958. Archived from the original on 20 August 2017.
Khera, AV; Kathiresan, S (June 2017). "Genetics of coronary artery disease: discovery, biology and clinical translation". Nature Reviews Genetics. 18 (6): 331–344. doi:10.1038/nrg.2016.160. PMC 5935119. PMID 28286336.
Mu, Fan; Rich-Edwards, Janet; Rimm, Eric B.; Spiegelman, Donna; Missmer, Stacey A. (29 March 2016). "Endometriosis and Risk of Coronary Heart Disease". Circulation: Cardiovascular Quality and Outcomes. 9 (3): 257–264. doi:10.1161/CIRCOUTCOMES.115.002224. PMC 4940126. PMID 27025928. Retrieved 31 March 2016.
Albus, C (October 2010). "Psychological and social factors in coronary heart disease". Annals of Medicine. 42 (7): 487–94. doi:10.3109/07853890.2010.515605. PMID 20839918.
Felitti VJ, Anda RF, Nordenberg D, Williamson DF, Spitz AM, Edwards V, Koss MP, Marks JS (1998). "Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults". Am J Prev Med. 14 (4): 245–58. doi:10.1016/S0749-3797(98)00017-8. PMID 9635069.
Grant PJ (2003). "The genetics of atherothrombotic disorders: a clinician's view". J Thromb Haemost (Review). 1 (7): 1381–90. doi:10.1046/j.1538-7836.2003.00276.x. PMID 12871271.
Padmanaban P, Toora BD. Hemoglobin: Emerging marker in stable coronary artery disease. Chron Young Sci [serial online] 2011 [cited 2011 July 24];2:109–10. Available from: http://www.cysonline.org/text.asp?2011/2/2/109/82971
Fajar, J. K. (2016). The β fibrinogen gene G-455A polymorphism in Asian subjects with coronary heart disease: A meta analysis. Egyptian Journal of Medical Human Genetics.
Ambrose, John; Singh, Manmeet (2015). "Pathophysiology of coronary artery disease leading to acute coronary syndromes". F1000Prime Reports. 7: 08. doi:10.12703/P7-08. ISSN 2051-7599. PMC 4311268. PMID 25705391.
Aziz, S (2005). "Chronic total occlusions—a stiff challenge requiring a major breakthrough: is there light at the end of the tunnel?". Heart. 91 (suppl_3): iii42–iii48. doi:10.1136/hrt.2004.058495. ISSN 1355-6037. PMC 1876352. PMID 15919653.
Lanza GA (February 2007). "Cardiac syndrome X: a critical overview and future perspectives". Heart. 93 (2): 159–66. doi:10.1136/hrt.2005.067330. PMC 1861371. PMID 16399854.
Jones E, Eteiba W, Merz NB (August 2012). "Cardiac syndrome X and microvascular coronary dysfunction". Trends in Cardiovascular Medicine. 22 (6): 161–68. doi:10.1016/j.tcm.2012.07.014. PMC 3490207. PMID 23026403.
Petersen, JW; Pepine, CJ (February 2015). "Microvascular coronary dysfunction and ischemic heart disease: where are we in 2014?". Trends in cardiovascular medicine. 25 (2): 98–103. doi:10.1016/j.tcm.2014.09.013. PMID 25454903.
Kaski JC (February 2004). "Pathophysiology and management of patients with chest pain and normal coronary arteriograms (cardiac syndrome X)". Circulation. 109 (5): 568–72. doi:10.1161/01.CIR.0000116601.58103.62. PMID 14769677.
American Society of Echocardiography. "Five Things Physicians and Patients Should Question". Choosing Wisely: An Initiative of the ABIM Foundation. Archived from the original on 26 February 2013. Retrieved 27 February 2013., citing
Douglas PS, Garcia MJ, Haines DE, Lai WW, Manning WJ, Patel AR, Picard MH, Polk DM, Ragosta M, Ward RP, Weiner RB (2011). "ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography". Journal of the American College of Cardiology. 57 (9): 1126–66. doi:10.1016/j.jacc.2010.11.002. PMID 21349406.
Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, Ferguson TB, Fihn SD, Fraker TD, Gardin JM, O'Rourke RA, Pasternak RC, Williams SV (2003). "ACC/AHA 2002 guideline update for the management of patients with chronic stable angina—summary article". Journal of the American College of Cardiology. 41 (1): 159–68. doi:10.1016/S0735-1097(02)02848-6. PMID 12570960.
Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, Foster E, Hlatky MA, Hodgson JM, Kushner FG, Lauer MS, Shaw LJ, Smith SC, Taylor AJ, Weintraub WS, Wenger NK, Jacobs AK, Smith SC, Anderson JL, Albert N, Buller CE, Creager MA, Ettinger SM, Guyton RA, Halperin JL, Hochman JS, Kushner FG, Nishimura R, Ohman EM, Page RL, Stevenson WG, Tarkington LG, Yancy CW (2010). "2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults". Journal of the American College of Cardiology. 56 (25): e50–103. doi:10.1016/j.jacc.2010.09.001. PMID 21144964.
American College of Cardiology (September 2013), "Five Things Physicians and Patients Should Question", Choosing Wisely: an initiative of the ABIM Foundation, American College of Cardiology, archived from the original on 17 December 2013, retrieved 10 February 2014
"Coronary Angiography". National Heart, Blood, and Lung Institute. Retrieved 10 December 2017.
Li, Y. Robert (2015), "Chapter 13: Overview of ischemic heart disease, stable angina, and drug therapy", Cardiovascular Diseases: From Molecular Pharmacology to Evidence-Based Therapeutics (1st ed.), John Wiley and Sons, ISBN 978-0-470-91537-0.
Fihn, SD; et al. (2014), "2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons", Circulation, 30 (19): 1749–1767, doi:10.1161/CIR.0000000000000095, PMID 25070666.
European Society of Cardiology (2014), Stable Coronary Artery Disease (Management of): ESC Clinical Practice Guidelines, retrieved 2017-09-14.
McGill, Henry C.; McMahan, C. Alex; Gidding, Samuel S. (2008-03-04). "Preventing Heart Disease in the 21st Century". Circulation. 117 (9): 1216–1227. doi:10.1161/CIRCULATIONAHA.107.717033. ISSN 0009-7322. PMID 18316498.
McNeal, Catherine J.; Dajani, Tala; Wilson, Don; Cassidy-Bushrow, Andrea E.; Dickerson, Justin B.; Ory, Marcia (2010-01-01). "Hypercholesterolemia in youth: opportunities and obstacles to prevent premature atherosclerotic cardiovascular disease". Current Atherosclerosis Reports. 12 (1): 20–28. doi:10.1007/s11883-009-0072-0. ISSN 1534-6242. PMID 20425267.
Naci, H.; Ioannidis, J. P. A. (1 October 2013). "Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study". BMJ. 347 (oct01 1): f5577. doi:10.1136/bmj.f5577. PMC 3788175. PMID 24473061.
Kyu, Hmwe H; Bachman, Victoria F; Alexander, Lily T; Mumford, John Everett; Afshin, Ashkan; Estep, Kara; Veerman, J Lennert; Delwiche, Kristen; Iannarone, Marissa L; Moyer, Madeline L; Cercy, Kelly; Vos, Theo; Murray, Christopher J L; Forouzanfar, Mohammad H (9 August 2016). "Physical activity and risk of breast cancer, colon cancer, diabetes, ischemic heart disease, and ischemic stroke events: systematic review and dose-response meta-analysis for the Global Burden of Disease Study 2013". BMJ. 354: i3857. doi:10.1136/bmj.i3857. PMC 4979358. PMID 27510511.
Ebrahim, Shah; Taylor, Fiona; Ward, Kirsten; Beswick, Andrew; Burke, Margaret; Davey Smith, George (19 January 2011). "Cochrane Database of Systematic Reviews". Cochrane Database of Systematic Reviews (1): CD001561. doi:10.1002/14651858.cd001561.pub3. PMID 21249647.
"5. Population nutrient intake goals for preventing diet-related chronic diseases". WHO. Archived from the original on 29 December 2015. Retrieved 26 October 2015.
Wang, X; Ouyang, Y; Liu, J; Zhu, M; Zhao, G; Bao, W; Hu, FB (29 July 2014). "Fruit and vegetable consumption and mortality from all causes, cardiovascular disease, and cancer: systematic review and dose-response meta-analysis of prospective cohort studies". BMJ (Clinical Research Ed.). 349: g4490. doi:10.1136/bmj.g4490. PMC 4115152. PMID 25073782.
Li, D (30 January 2014). "Effect of the vegetarian diet on non-communicable diseases". Journal of the Science of Food and Agriculture. 94 (2): 169–73. doi:10.1002/jsfa.6362. PMID 23965907.
Huang, T; Yang, B; Zheng, J; Li, G; Wahlqvist, ML; Li, D (2012). "Cardiovascular disease mortality and cancer incidence in vegetarians: a meta-analysis and systematic review". Annals of Nutrition and Metabolism. 60 (4): 233–40. doi:10.1159/000337301. PMID 22677895.
Ginter, E (2008). "Vegetarian diets, chronic diseases and longevity". Bratislavske Lekarske Listy. 109 (10): 463–6. PMID 19166134.
Walker C, Reamy BV (April 2009). "Diets for cardiovascular disease prevention: what is the evidence?". Am Fam Physician. 79 (7): 571–8. PMID 19378874.
Threapleton DE, Greenwood DC, Evans CE, Cleghorn CL, Nykjaer C, Woodhead C, Cade JE, Gale CP, Burley VJ (2013). "Dietary fibre intake and risk of cardiovascular disease: systematic review and meta-analysis". BMJ. 347: f6879. doi:10.1136/bmj.f6879. PMC 3898422. PMID 24355537.
Lopez-Garcia E, Schulze MB, Meigs JB, Manson JE, Rifai N, Stampfer MJ, Willett WC, Hu FB (2005). "Consumption of trans fatty acids is related to plasma biomarkers of inflammation and endothelial dysfunction". J Nutr. 135 (3): 562–66. doi:10.1093/jn/135.3.562. PMID 15735094.
Mozaffarian D, Katan MB, Ascherio A, Stampfer MJ, Willett WC (April 2006). "Trans fatty acids and cardiovascular disease". N. Engl. J. Med. 354 (15): 1601–13. doi:10.1056/NEJMra054035. PMID 16611951.
Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS (September 2012). "Association Between Omega-3 Fatty Acid Supplementation and Risk of Major Cardiovascular Disease Events A Systematic Review and Meta-analysis". JAMA. 308 (10): 1024–1033. doi:10.1001/2012.jama.11374. PMID 22968891.
Kwak SM, Myung SK, Lee YJ, Seo HG (2012-04-09). "Efficacy of Omega-3 Fatty Acid Supplements (Eicosapentaenoic Acid and Docosahexaenoic Acid) in the Secondary Prevention of Cardiovascular Disease: A Meta-analysis of Randomized, Double-blind, Placebo-Controlled Trials". Archives of Internal Medicine. 172 (9): 686–94. doi:10.1001/archinternmed.2012.262. PMID 22493407.
Erkkilä AT, Booth SL (2008). "Vitamin K intake and atherosclerosis". Curr. Opin. Lipidol. 19 (1): 39–42. doi:10.1097/MOL.0b013e3282f1c57f. PMID 18196985.
Linden W, Stossel C, Maurice J (April 1996). "Psychosocial interventions for patients with coronary artery disease: a meta-analysis". Arch. Intern. Med. 156 (7): 745–52. doi:10.1001/archinte.1996.00440070065008. PMID 8615707.
Swardfager W, Herrmann N, Cornish S, Mazereeuw G, Marzolini S, Sham L, Lanctôt KL (2012). "Exercise intervention and inflammatory markers in coronary artery disease: a meta-analysis". Am Heart J. 163 (4): 666–76. doi:10.1016/j.ahj.2011.12.017. PMID 22520533. Retrieved 26 October 2015.
How to Increase Your HDL Cholesterol Levels Archived 14 July 2006 at the Wayback Machine.; accessed 26 October 2015.
"Coronary Heart Disease (CHD)". Penguin Dictionary of Biology. 2004.
U.S. Preventive Services Task Force (2002). "Behavioral counseling in primary care to promote physical activity: recommendation and rationale". Ann. Intern. Med. 137 (3): 205–07. doi:10.7326/0003-4819-137-3-200208060-00014. PMID 12160370.
Thompson PD, Buchner D, Pina IL, Balady GJ, Williams MA, Marcus BH, Berra K, Blair SN, Costa F, Franklin B, Fletcher GF, Gordon NF, Pate RR, Rodriguez BL, Yancey AK, Wenger NK (2003). "Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity)". Circulation. 107 (24): 3109–16. doi:10.1161/01.CIR.0000075572.40158.77. PMID 12821592.
Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease. Major Recommendations Archived 22 October 2007 at the Wayback Machine.; accessed 26 October 2015.
Jameson JN, Kasper DL, Harrison TR, Braunwald E, Fauci AS, Hauser SL, Longo DL (2005). Harrison's principles of internal medicine (16th ed.). New York: McGraw-Hill Medical Publishing Division. ISBN 978-0-07-140235-4. OCLC 54501403. Archived from the original on 19 February 2014. Retrieved 26 October 2015.
Gutierrez J, Ramirez G, Rundek T, Sacco RL (25 June 2012). "Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis". Archives of Internal Medicine. 172 (12): 909–19. doi:10.1001/archinternmed.2012.2145. PMID 22732744.
"Nitroglycerin Sublingual: MedlinePlus Drug Information". medlineplus.gov. Archived from the original on 6 January 2017.
Ohman, EM (March 2016). "CLINICAL PRACTICE. Chronic Stable Angina". New England Journal of Medicine. 374 (12): 1167–76. doi:10.1056/NEJMcp1502240. PMID 27007960.
Grove, EL; Würtz, M; Thomas, MR; Kristensen, SD (2015). "Antiplatelet therapy in acute coronary syndromes". Expert Opinion on Pharmacotherapy (Review). 16 (14): 2133–47. doi:10.1517/14656566.2015.1079619. PMID 26293612.
Rosendorff, C; Lackland, DT; Allison, M; Aronow, WS; Black, HR; Blumenthal, RS; Cannon, CP; de Lemos, JA; Elliott, WJ; Findeiss, L; Gersh, BJ; Gore, JM; Levy, D; Long, JB; O'Connor, CM; O'Gara, PT; Ogedegbe, O; Oparil, S; White, WB (31 March 2015). "Treatment of Hypertension in Patients With Coronary Artery Disease: A Scientific Statement From the American Heart Association, American College of Cardiology, and American Society of Hypertension". Circulation. 131 (19): e435–70. doi:10.1161/cir.0000000000000207. PMID 25829340.
Guirguis-Blake, JM; Evans, CV; Senger, CA; O'Connor, EA; Whitlock, EP (21 June 2016). "Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services Task Force". Annals of Internal Medicine (Systematic Review and Meta-Analysis). 164 (12): 804–13. doi:10.7326/M15-2113. PMID 27064410.
U.S. Preventive Services Task Force (15 January 2002). "Aspirin for the primary prevention of cardiovascular events: recommendation and rationale". Ann Intern Med. 136 (2): 157–60. doi:10.7326/0003-4819-136-2-200201150-00015. PMID 11790071. Archived from the original on 6 October 2009. Retrieved 26 October 2015.
Squizzato, Alessandro; Keller, Tymen; Romualdi, Erica; Middeldorp, Saskia (2011-01-19). "Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease". The Cochrane Database of Systematic Reviews (1): CD005158. doi:10.1002/14651858.CD005158.pub3. ISSN 1469-493X. PMID 21249668.
"FDA Drug Safety Communication: FDA review finds long-term treatment with blood-thinning medicine Plavix (clopidogrel) does not change risk of death". FDA. 6 November 2015. Archived from the original on 4 February 2016. Retrieved 25 January 2016.
Elmariah, Sammy; Mauri, Laura; Doros, Gheorghe; Galper, Benjamin Z; O'Neill, Kelly E; Steg, Philippe Gabriel; Kereiakes, Dean J; Yeh, Robert W (November 2014). "Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis". The Lancet. 385 (9970): 792–798. doi:10.1016/S0140-6736(14)62052-3. PMC 4386690. PMID 25467565.
Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith EE, Steward DE, Theroux P, Gibbons RJ, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Hiratzka LF, Jacobs AK, Smith SC (October 2002). "ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction—2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina)". Circulation. 106 (14): 1893–1900. doi:10.1161/01.CIR.0000037106.76139.53. PMID 12356647. Archived from the original on 3 July 2011. Retrieved 26 October 2015.
Stergiopoulos K, Boden WE, Hartigan P, Möbius-Winkler S, Hambrecht R, Hueb W, Hardison RM, Abbott JD, Brown DL (2014). "Percutaneous coronary intervention outcomes in patients with stable obstructive coronary artery disease and myocardial ischemia: a collaborative meta-analysis of contemporary randomized clinical trials". JAMA Intern Med. 174 (2): 232–40. doi:10.1001/jamainternmed.2013.12855. PMID 24296791.
Sipahi I, Akay MH, Dagdelen S, Blitz A, Alhan C (2014). "Coronary artery bypass grafting vs percutaneous coronary intervention and long-term mortality and morbidity in multivessel disease: meta-analysis of randomized clinical trials of the arterial grafting and stenting era". JAMA Intern Med. 174 (2): 223–30. doi:10.1001/jamainternmed.2013.12844. PMID 24296767.
Sipahi I, Akay MH, Dagdelen S, Blitz A, Alhan C (1 February 2014). "Coronary artery bypass grafting vs percutaneous coronary intervention and long-term mortality and morbidity in multivessel disease: meta-analysis of randomized clinical trials of the arterial grafting and stenting era". JAMA Internal Medicine. 174 (2): 223–30. doi:10.1001/jamainternmed.2013.12844. PMID 24296767.
Zhao, Dong Fang (28 February 2017). "Coronary Artery Bypass Grafting With and Without Manipulation of the Ascending Aorta: A Network Meta-Analysis". Journal of the American College of Cardiology. 69 (8): 924–936. doi:10.1016/j.jacc.2016.11.071. PMID 28231944. Archived from the original on 28 February 2017.
Reynolds, AC; King, N (2018). "Hybrid coronary revascularization versus conventional coronary artery bypass grafting: Systematic review and meta-analysis". Medicine (Baltimore). 97 (33): e11941. doi:10.1097/MD.0000000000011941. PMC 6112891. PMID 30113498.
"WHO Disease and injury country estimates". World Health Organization. 2009. Archived from the original on 11 November 2009. Retrieved 11 November 2009.
Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, et al. (15 December 2012). "Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010". Lancet. 380 (9859): 2095–2128. doi:10.1016/S0140-6736(12)61728-0. hdl:10536/DRO/DU:30050819. PMID 23245604.
Finegold JA, Asaria P, Francis DP (4 December 2012). "Mortality from ischaemic heart disease by country, region, and age: Statistics from World Health Organisation and United Nations". International Journal of Cardiology. 168 (2): 934–45. doi:10.1016/j.ijcard.2012.10.046. PMC 3819990. PMID 23218570.
Indian Heart Association Why South Asians Facts Archived 18 May 2015 at the Wayback Machine., 29 April 2015; accessed 26 October 2015.
"Kochanek KD, Xu JQ, Murphy SL, Miniño AM, Kung HC" (PDF). Archived (PDF) from the original on 16 January 2013. Retrieved 25 March 2013.
Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, Haase N, Ho M, Howard V, Kissela B, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell CJ, Roger V, Rumsfeld J, Sorlie P, Steinberger J, Thom T, Wasserthiel-Smoller S, Hong Y (February 2007). "Heart disease and stroke statistics—2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee". Circulation. 115 (5): e69–171. doi:10.1161/CIRCULATIONAHA.106.179918. PMID 17194875. Archived from the original on 8 June 2011. Retrieved 26 October 2015.
American Heart Association:Heart Disease and Stroke Statistics-2007 Update. AHA, Dallas, Texas, 2007 Archived 1 July 2007 at the Wayback Machine.
"Other Names for Coronary Heart Disease". 29 September 2014. Archived from the original on 13 February 2015. Retrieved 23 February 2015.
ICP, bmj.com; accessed 25 October 2015.
Infarct Combat Project website Archived 12 August 2015 at the Wayback Machine.; accessed 26 October 2015.
O'Connor, Anahad, "How the Sugar Industry Shifted Blame to Fat" Archived 28 February 2017 at the Wayback Machine., The New York Times, September 12, 2016. Retrieved 2016-09-12.
Kearns, CE; Schmidt, LA; Glantz, SA (12 September 2016). "Sugar Industry and Coronary Heart Disease Research: A Historical Analysis of Internal Industry Documents". JAMA Internal Medicine. 176 (11): 1680–1685. doi:10.1001/jamainternmed.2016.5394. PMC 5099084. PMID 27617709.
Nestle, Marion (12 September 2016). "Invited Commentary:Food Industry Funding of Nutrition Research: The Relevance of History for Current Debates". JAMA Internal Medicine. 176 (11): 1685–1686. doi:10.1001/jamainternmed.2016.5400. PMID 27618496.
Deena Shanker (12 September 2016). "How Big Sugar Enlisted Harvard Scientists to Influence How We Eat—in 1965". Bloomberg News. Archived from the original on 2 February 2017.
Ifill, Gwen (13 September 2016). "How the sugar industry paid experts to downplay health risks". PBS NewsHour. Archived from the original on 20 August 2017.
Farrall M, Green FR, Peden JF, Olsson PG, Clarke R, Hellenius ML, Rust S, Lagercrantz J, Franzosi MG, Schulte H, Carey A, Olsson G, Assmann G, Tognoni G, Collins R, Hamsten A, Watkins H (2006). "Genome-Wide Mapping of Susceptibility to Coronary Artery Disease Identifies a Novel Replicated Locus on Chromosome 17". PLoS Genetics. 2 (5): e72. doi:10.1371/journal.pgen.0020072. PMC 1463045. PMID 16710446.
Roberts, R; Stewart, AF (January 2012). "9p21 and the genetic revolution for coronary artery disease". Clinical Chemistry. 58 (1): 104–12. doi:10.1373/clinchem.2011.172759. PMID 22015375.
Dandona, S; Stewart, AF; Roberts, R (March 2010). "Genomics in coronary artery disease: past, present and future". The Canadian Journal of Cardiology. 26 Suppl A: 56A–59A. doi:10.1016/s0828-282x(10)71064-3. PMID 20386763.
Saikku P, Leinonen M, Tenkanen L, Linnanmäki E, Ekman MR, Manninen V, Mänttäri M, Frick MH, Huttunen JK (1992). "Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study". Annals of Internal Medicine. 116 (4): 273–78. doi:10.7326/0003-4819-116-4-273. PMID 1733381.
Grayston, JT; Belland, RJ; Byrne, GI; Kuo, CC; Schachter, J; Stamm, WE; Zhong, G (February 2015). "Infection with Chlamydia pneumoniae as a cause of coronary heart disease: the hypothesis is still untested". Pathogens and Disease. 73 (1): 1–9. doi:10.1093/femspd/ftu015. PMC 4492408. PMID 25854002.
Andrews R, Berger JS, Brown DL (2005). "Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analysis of randomized controlled trials". JAMA. 293 (21): 2641–47. doi:10.1001/jama.293.21.2641. PMID 15928286.
Simons M, Bonow RO, Chronos NA, Cohen DJ, Giordano FJ, Hammond HK, Laham RJ, Li W, Pike M, Sellke FW, Stegmann TJ, Udelson JE, Rosengart TK (September 2000). "Clinical trials in coronary angiogenesis: issues, problems, consensus: An expert panel summary". Circulation. 102 (11): E73–86. doi:10.1161/01.CIR.102.11.e73. PMID 10982554. Retrieved 26 October 2015.
Stegmann TJ (December 1998). "FGF-1: a human growth factor in the induction of neoangiogenesis". Expert Opin Investig Drugs. 7 (12): 2011–15. doi:10.1517/13543784.7.12.2011. PMID 15991943.
Wagoner L.E.; Merrill W.; Jacobs J.; Conway G.; Boehmer J.; Thomas K.; Stegmann T.J. (2007). "Angiogenesis Protein Therapy With Human Fibroblast Growth Factor (FGF-1) Results of a Phase I Open Label, Dose Escalation Study in Subjects With CAD Not Eligible For PCI Or CABG". Circulation. 116: 443. Archived from the original on 15 October 2015.
Loria V, Dato I, Graziani F, Biasucci LM (2008). "Myeloperoxidase: a new biomarker of inflammation in ischemic heart disease and acute coronary syndromes". Mediators Inflamm. 2008: 135625. doi:10.1155/2008/135625. PMC 2276594. PMID 18382609.
Esselstyn, C. B. (2001-01-01). "Resolving the Coronary Artery Disease Epidemic Through Plant-Based Nutrition". Preventive Cardiology. 4 (4): 171–177. doi:10.1111/j.1520-037x.2001.00538.x. ISSN 1751-7141. PMID 11832674. |
